CEO Innovation Policy Update 11.19.26

Nov 19, 2026

With Democrats set to take control of Congress in January, the lame-duck session is increasingly defined by what Republicans can finish and what will carry into the new year.

At a glance

  • FDA commissioner: The White House withdrew Heidi Overton’s nomination a day before her HELP Committee vote. Confirming a permanent commissioner will likely fall to the incoming Democratic majority unless Republicans move fast on a replacement such as Sen. Roger Marshall. Kyle Diamantas stays on as acting commissioner.
  • OMB grant rule (block expires Dec. 11): None of the Senate’s 12 FY27 spending bills extends the block on OMB’s grant overhaul, which MassBio opposes. Leaders in both parties support carrying the block forward in the next stopgap. MassBio will keep engaging.
  • Drug pricing and patents: Senate Judiciary members from both parties criticized PBMs and backed a package of drug competition bills, with some pushing for a floor vote before year-end. Democrats previewed expanded Medicare negotiation for the new Congress.
  • NIAID: Dr. John H. Powers III, now permanent director, is moving the institute’s focus away from HIV, civilian biodefense and pandemic preparedness. Massachusetts institutions with NIAID funding should watch for shifts in funding priorities.
  • China (BIOSECURE list due Dec. 18): A House hearing today looks at China’s hold on pharmaceutical supply chains, ahead of the administration’s first list of biotech companies of concern. MassBio will share takeaways with members.

Here’s what we’re watching this week:

White House Withdraws Overton Nomination for FDA Commissioner: The White House withdrew Heidi Overton’s nomination just one day before her scheduled HELP Committee vote, following concerns raised from Republican senators about her positions on key health policy issues that threatened to derail her confirmation. Chairman Bill Cassidy (R-LA) maintained that Overton would have had the necessary votes, but acknowledged that confirming a permanent commissioner now likely falls to incoming HELP Chair Bernie Sanders (I-VT) and the Democratic majority. Republicans have discussed Sen. Roger Marshall (R-KS), a physician, and HELP Committee member who lost his re-election bid, as a potential replacement who could be confirmed quickly before the Senate changes hands. In the meantime, Kyle Diamantas will continue serving as acting commissioner, a role he has held since May. 

FY27 Spending Bills Leave OMB Grant Rule Unaddressed: The Senate Appropriations Committee has released all twelve of its FY27 funding bills, none of which would extend the current block on OMB’s overhaul of federal grant funding rules. The proposal, which MassBio submitted comments strongly opposing, would require pre-issuance review of discretionary grants by political appointees, expand authority to terminate active awards, and restrict allowable costs, including publication and open-access fees. Congress temporarily blocked implementation through the September stopgap, which expires December 11. With none of the full-year bills expected to advance by that deadline, another short-term continuing resolution appears to be the most likely vehicle. Senate Appropriations Chair Susan Collins (R-ME) indicated that she supports carrying the prohibition forward in that resolution, and Senate Democrats have said they will also push to extend it. Incoming House Appropriations Chair Rosa DeLauro (D-CT) has separately indicated that any final FY27 agreement must include language blocking the rule. MassBio will continue to engage on this issue on behalf of the early-stage researchers developing tomorrow’s breakthroughs.

Senate Judiciary Examines Drug Competition and Patent Reform: On November 17, the Senate Judiciary Committee held a hearing titled “Prescribing Sunshine: How Competition & Transparency Lower Prescription Drug Costs,” which focused largely on pharmacy benefit managers (PBMs) and pharmacy access. Members on both sides of the aisle sharply criticized PBMs, citing their market concentration and the closure of independent pharmacies, with some calling for structural changes such as breaking up the largest companies and emphasizing greater transparency. Members also voiced bipartisan support for a package of committee-reported drug competition bills addressing patent thickets, product hopping, pay-for-delay agreements, and coordination between FDA and the USPTO, with several pushing for floor action before the end of the year. Democratic members raised proposals to expand Medicare drug price negotiation and extend inflation rebates to all drugs, previewing likely priorities for the new Congress. 

NIH Names New NIAID Director: On November 16, NIH named Dr. John H. Powers III, who has served as acting director since June, as permanent director of the National Institute of Allergy and Infectious Diseases (NIAID). Powers is an infectious disease clinician who previously worked at FDA and as a longtime NIH contractor. At Monday’s announcement, Powers reaffirmed the direction he outlined with NIH leadership in January, which scales back work on HIV, civilian biodefense, and pandemic preparedness in favor of the infectious diseases most affecting Americans today and fundamental immunology research. Massachusetts research institutions and companies with NIAID-funded work will want to watch how the institute’s priorities continue to shape future funding opportunities.

House Panel to Examine China’s Role in Pharmaceutical Supply Chains: The House Foreign Affairs Subcommittee on East Asia and Pacific will hold a hearing on November 19 titled “The Hidden Chokepoint: China’s Dominance in Pharmaceuticals.” The hearing comes as the administration prepares to release its initial list of biotechnology companies of concern under the BIOSECURE Act by December 18, and keeps U.S.–China biotech relations in focus as Congress prepares for the new session. MassBio will be watching the hearing closely and will share key takeaways with members.

See all MassBio News